2-(cyclohexylmethoxy)isoindoline-1,3-dione | 113211-23-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(cyclohexylmethoxy)isoindoline-1,3-dione
• 英文别名: 2-(cyclohexylmethoxy)-1H-isoindole-1,3(2H)-dione；N-Cyclohexylmethoxyphthalimide；2-(cyclohexylmethoxy)isoindole-1,3-dione
• CAS: 113211-23-7
• 化学式: C₁₅H₁₇NO₃
• 分子量: 259.305
• InChiKey: XWWCWCVXXGNINI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(cyclohexylmethoxy)isoindoline-1,3-dione 在 一水合肼 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 3.5h， 生成 N-(cyclohexylmethoxy)-6-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-hexanesulfonamide
  参考文献：
  名称：

  Nicotinamide Phosphoribosyltransferase Inhibitors, Design, Preparation, and Structure–Activity Relationship

  摘要：

  Existing pharmacological inhibitors for nicotinamide phosphoribosyltransferase (NAMPT) are promising therapeutics for treating cancer. By using medicinal and computational chemistry methods, the structure-activity relationship for novel classes of NAMPT inhibitors is described, and the compounds are optimized. Compounds are designed inspired by the NAMPT inhibitor APO866 and cyanoguanidine inhibitor scaffolds. In comparison with recently published derivatives, the new analogues exhibit an equally potent antiproliferative activity in vitro and comparable activity in vivo. The best performing compounds from these series showed subnanomolar antiproliferative activity toward a series of cancer cell lines (compound 15: IC50 0.025 and 0.33 nM, in A2780 (ovarian carcinoma) and MCF-7 (breast), respectively) and potent antitumor in vivo activity in well-tolerated doses in a xenograft model. In an A2780 xenograft mouse model with large tumors (500 mm(3)), compound 15 reduced the tumor volume to one-fifth of the starting volume at a dose of 3 mg/kg administered ip, bid, days 1-9. Thus, compounds found in this study compared favorably with compounds already in the clinic and warrant further investigation as promising lead molecules for the inhibition of NAMPT.

  DOI：

  10.1021/jm4009949
• 作为产物：
  描述：

  N-羟基邻苯二甲酰亚胺 、 溴甲基环己烷 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以99%的产率得到2-(cyclohexylmethoxy)isoindoline-1,3-dione
  参考文献：
  名称：

  NOVEL VASCULAR LEAKAGEAGE INHIBITOR

  摘要：

  本公开涉及一种新型血管渗漏抑制剂。本发明的新型血管渗漏抑制剂抑制血管内皮细胞凋亡，抑制由VEGF诱导的肌动蛋白应激纤维的形成，并增强皮质肌动蛋白环结构，从而抑制血管渗漏。因此，本发明的血管渗漏抑制剂可以预防或治疗由血管渗漏引起的各种疾病。由于本发明的血管渗漏抑制剂是由商业可获得或易于合成的孕酮合成的，因此具有明显优越的商业合成可行性。

  公开号：

  US20140378399A1

文献信息

• Sulfonamide inhibitors of aspartyl protease
  申请人：——

  公开号：US20020049201A1

  公开（公告）日：2002-04-25

  The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

  本发明涉及一类新型磺胺类化合物，其为天冬氨酸蛋白酶抑制剂。在一个实施例中，本发明涉及一类新型HIV天冬氨酸蛋白酶抑制剂，其具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制HIV-1和HIV-2蛋白酶活性，因此，可以有利地用作抗HIV-1和HIV-2病毒的抗病毒剂。本发明还涉及使用本发明的化合物抑制HIV天冬氨酸蛋白酶活性的方法以及筛选具有抗HIV活性的化合物的方法。
• Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives
  申请人：Meyer Gerhard Adam

  公开号：US20060063841A1

  公开（公告）日：2006-03-23

  Novel trifluoromethanesulfonanilide oxime ether compounds useful for controlling endo and/or ectoparasites in the environment are provided, together with methods of making the same, and methods of using the inventive compounds to treat parasite infestations in vivo or ex vivo.

  提供了一种新型三氟甲磺酰苯胺肟醚化合物，可用于控制环境中的内寄生虫和/或外寄生虫，同时提供了制备这些化合物的方法，以及利用这些创新化合物治疗体内或体外寄生虫感染的方法。
• Photoinduced Fragmentation Borylation of Cyclic Alcohols and Hemiacetals
  作者：Chao Shu、Rudrakshula Madhavachary、Adam Noble、Varinder K. Aggarwal

  DOI：10.1021/acs.orglett.0c02513

  日期：2020.9.18

  conveniently prepared by radical-mediated ring opening of cyclic alcohols and hemiacetals, respectively. The reactions proceed under mild conditions in the absence of additives or photocatalysts, display excellent functional group tolerance, and are shown to allow cleavage of 4-, 5-, 6-, and 7-membered ring substrates. The mechanism proceeds via sequential homolytic N–O and C–C bond cleavages, the latter

  O的可见光光致碎裂硼化描述了具有双（邻苯二酚）二硼的邻苯二甲酰亚胺基环烷醇。分别通过环状醇和半缩醛的自由基介导的开环，可以方便地制备结构多样的酮基和甲酰氧基烷基硼酸酯。反应在没有添加剂或光催化剂的条件下在温和条件下进行，显示出极好的官能团耐受性，并显示可裂解4、5、6和7元环底物。其机理是通过顺序的均相N–O和C–C键裂解来进行的，后者的裂解涉及烷氧基的β断裂，生成羰基和被二硼试剂捕获的烷基。光谱研究表明，用蓝光直接对邻苯二甲酰亚胺或乙硼烷底物进行光激发可引发自由基链机制。
• NOVEL VASCULAR LEAKAGEAGE INHIBITOR
  申请人：Industry-Academic Cooperation Foundation, Yonsei University

  公开号：US20140378399A1

  公开（公告）日：2014-12-25

  The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, and enhances the cortical actin ring structure, thereby inhibiting vascular leakage. Accordingly, the vascular leakage inhibitor of the present invention can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present invention is synthesized from commercially available or easily synthesizable pregnenolones, it has remarkably superior feasibility of commercial synthesis.

  本公开涉及一种新型血管渗漏抑制剂。本发明的新型血管渗漏抑制剂抑制血管内皮细胞凋亡，抑制由VEGF诱导的肌动蛋白应激纤维的形成，并增强皮质肌动蛋白环结构，从而抑制血管渗漏。因此，本发明的血管渗漏抑制剂可以预防或治疗由血管渗漏引起的各种疾病。由于本发明的血管渗漏抑制剂是由商业可获得或易于合成的孕酮合成的，因此具有明显优越的商业合成可行性。
• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US06310095B1

  公开（公告）日：2001-10-30

  Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from (a) (b) —C(O)NH—CH(R14)—C(O)OR15, (d) —C(O)NH—CH(R14)—C(O)NHSO2R16, (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is substituted or unsubstituted heterocyclic or aryl, substituted or unsubstituted cycloalkyl or cycloalkenyl, and —P(W)RR3RR3′; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4—L6—C(W)—N(R5)—L5—, (e) —L4—L6—S(O)m—N(R5)—L5 —, (f) —L4—N(R5)—C(W)—L7—L5—, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, (j) optionally substituted alkynylene (k) a covalent bond, (l) and (m) are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下化学式或其药学上可接受的盐，其中R1为(a)氢，(b)低碳基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2-，以及(i)杂环-L2-；R2选自(a)、(b)、—C(O)NH—CH(R14)—C(O)OR15、(d)、—C(O)NH—CH(R14)—C(O)NHSO2R16、(e)、—C(O)NH—CH(R14)-四唑基、(f)、—C(O)NH-杂环，以及(g)、—C(O)NH—CH(R14)—C(O)NR17R18；R3是取代或未取代的杂环或芳基，取代或未取代的环烷基或环烯基，以及—P(W)RR3RR3′；R4为氢、低碳基、卤代烷基、卤素、芳基、芳基烷基、杂环或(杂环)烷基；L1不存在或选自(a)、—L4—N(R5)—L5—、(b)、—L4—O—L5—、(c)、—L4—S(O)n—L5—、(d)、—L4—L6—C(W)—N(R5)—L5—、(e)、—L4—L6—S(O)m—N(R5)—L5—、(f)、—L4—N(R5)—C(W)—L7—L5—、(g)、—L4—N(R5)—S(O)p—L7—L5—、(h)、可选取代的烷基、(i)、可选取代的烯基、(j)、可选取代的炔基、(k)、共价键、(l)和(m)是蛋白异戊烯基转移酶的抑制剂。还公开了蛋白异戊烯基转移酶抑制剂组合物和一种抑制蛋白异戊烯基转移酶的方法。